Product Description
Mechanisms of Action: DNA Damager
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India
Approved Indications: None
Known Adverse Events: None
Company: Dr. Reddy's Laboratories
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Skin Diseases, Bacterial|Communicable Diseases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01875939 |
W 771/2349-101 | P1 |
Completed |
Healthy Volunteers |
2013-06-01 |
2019-03-19 |
Treatments |
|
NCT05640531 |
WCK771/P-I/MD/08 | P1 |
Completed |
Healthy Volunteers |
2012-02-07 |
2022-12-08 |
Primary Endpoints|Treatments |
|
NCT03405064 |
W-771/2349-301 | P3 |
Completed |
Skin Diseases, Bacterial|Communicable Diseases |
2018-09-25 |
21% |
2019-08-10 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |